Amphastar Pharmaceuticals Inc. Common Stock (AMPH)

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of interm…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

1,976

Website

amphastar.com/

Fundamentals

1-day range

$20.4$22.65

Market cap

$873.48M

P/E (trailing)

10.93

P/E (forward)

6.81

EPS (trailing)

$1.71

Dividend yield

—

Beta

0.92

Avg. volume

604.2K

Forecasts

6 analyst ratings

Amphastar Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• AMPH

  Amphastar Pharmaceuticals Inc. Common Stock

  $22.01

  ▲ 0.59%
  Market cap $873.48MP/E 10.93
  $16.65$31.26
• DSGN

  Design Therapeutics Inc. Common Stock

  $15.12

  ▼ 0.85%
  Market cap $861.75MP/E —
  $5.04$17.25
• ACRS

  Aclaris Therapeutics Inc. Common Stock

  $6.01

  ▼ 2.44%
  Market cap $850.55MP/E —
  $1.74$6.6
• ABUS

  Arbutus Biopharma Corporation Common Stock

  $5.07

  ▼ 1.93%
  Market cap $896.82MP/E 5.61
  $3.5$5.45
• ANNX

  Annexon Inc. Common Stock

  $4.97

  ▼ 5.33%
  Market cap $917.52MP/E —
  $2.03$7.18
• MNPR

  Monopar Therapeutics Inc. Common Stock

  $112.17

  ▼ 1.55%
  Market cap $805.29MP/E —
  $32.77$124.82
• COLL

  Collegium Pharmaceutical Inc. Common Stock

  $25.31

  ▼ 4.27%
  Market cap $944.15MP/E 19.04
  $25.16$50.79

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Monday's After-Market Session
  Benzinga · 8/24/2026
• Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate
  ChartMill · 8/15/2026
• Piper Sandler Maintains Neutral on Amphastar Pharma, Lowers Price Target to $20
  Benzinga · 8/7/2026
• Wells Fargo Maintains Equal-Weight on Amphastar Pharma, Raises Price Target to $20
  Benzinga · 8/7/2026
• Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/7/2026
• Amphastar Pharmaceuticals (NASDAQ:AMPH) Beats Q2 Earnings Estimates, Shares Rise After Hours
  ChartMill · 8/6/2026
• Amphastar Pharma Q2 Adj. EPS $0.91 Beats $0.62 Estimate, Sales $183.903M Beat $182.055M Estimate
  Benzinga · 8/6/2026

• William J. Peters · August 7, 2026 · Sale

  8.2K @ $22.48
• William J. Peters · August 7, 2026 · Option Exercise

  5.1K @ $19.79
• Anthony T. Pierce · July 9, 2026 · Grant

  16.6K
• Anthony T. Pierce · July 9, 2026 · Grant

  7.9K
• Howard Lee · June 2, 2026 · Tax Withholding

  769 @ $18.45
• David Russell Gaugh · June 1, 2026 · Grant

  17.4K
• David Russell Gaugh · June 1, 2026 · Grant

  8.1K
• Gayle Deflin · June 1, 2026 · Grant

  17.4K
• Gayle Deflin · June 1, 2026 · Grant

  8.1K
• Diane G. Gerst · June 1, 2026 · Grant

  17.4K
• Diane G. Gerst · June 1, 2026 · Grant

  8.1K
• Howard Lee · June 1, 2026 · Grant

  17.4K
• Howard Lee · June 1, 2026 · Grant

  8.1K
• Richard K. Prins · June 1, 2026 · Grant

  17.4K
• Richard K. Prins · June 1, 2026 · Grant

  8.1K

Institutional Ownership

March 31, 2026

Total shares held

30.92M

Total value held

$583.89M

Institutional holders

206